Bernstein Molho Rinat Dr. pectus Cancer

Haydn-Rinat Molho lectus a University of Dr. Israelis ad Haifa 2004. medicinae in schola illa perficitur per ea sedes et Oncology Medical an additional Medical Lindemuthianum residentia in acervum novarum frugum ad Medical Center. Quæ erat apud praefectum oncogenetic inhaero ad acervum novarum frugum Medical Center.

She joined pectus Cancer institute in the Sheba Medical Center at Tel Hashomer in 2017, where she works as a medical oncologist and clinical cancer geneticist. Her area of clinical and research interest is hereditary cancers.

Institutio et educatio

• Dr. Rinat Bernstein Molho lectus cum honores deferret illa res Facultatis medicae in Technion University, Haifa.
• Tunc specialized in Oncology ad Department of Oncology, Medical Center Tel Aviv.
• Illa etiam propria in genetics de Institute of Genetics, Medical Center Tel Aviv.

Publications

Accuratio PRAEDICTUM Risk est quia Pectus Cancri et in exemplum BRCA1 / Bacillus BRCA2 Portitorem Verisimilia in Israel. Kenan ES, Friger M, Shochat bigon, D, B Schayek, Molho-R Bernstein, M. Friedman

Quod autem plenus tradite BRCA1 / II Israelis in Genotyping summus periculo pectus / ovarian cancer aegris non portant plurimum mutationes. Barnes, et in Cedar mittite, Bernstein-R Molho, Ginzach N, S Hartmajer, Shapira T, N Magal, Kalis LM, id Phares T, M Shohat, Basel Salmon autem, L, E Friedman, Bazak L, M. Goldberg

Tolerability et iudicium et efficacia Carboplatin inveniet unitatem et in neoadjuvant anthracycline taxane Lorem fundatur in omnibus locupletati abundetis BRCA1 triplici negans pectus cancer cohortibus praepositi. Sella T, Gal Yam, Ethicorum, K Libano, Rotenberg T, M Gadot, Kuchuk Ego Molho RB, itai A, patota TM: Aurum R, Kaufman B Simon SP.

pectus Cancer